Table 2.
Treatment characteristics of all patients and stratified based on IBD subtype.
| All patients n = 191 |
UC n = 58 |
CD n = 109 |
IBDU n = 24 |
p-values* | |
|---|---|---|---|---|---|
| Any treatment | 124 (64.9) | 50 (86.2) | 66 (60.6) | 8 (33.3) | 0.001 |
| Oral mesalamine, n (%) | 93 (48.7) | 35 (60.3) | 51 (46.8) | 7 (29.2) | 0.10 |
| Rectal mesalamine, n (%) | 34 (17.8) | 25 (43.1) | 5 (4.6) | 4 (16.7) | 1.87* 10 − 7 |
| Steroids, n (%) | 35 (18.3) | 10 (17.2) | 23 (21.1) | 2 (8.3) | 0.55 |
| Azathioprine, n (%) | 13 (6.8) | 4 (6.9) | 9 (8.3) | 0 (0) | 0.76 |
| Methotrexate, n (%) | 5 (2.6) | 2 (3.4) | 3 (2.8) | 0 (0) | 0.80 |
| Biologics, n (%) | 34 (17.8) | 10 (17.2) | 23 (21.1) | 1 (4.2) | 0.55 |
| Surgical intervention, n (%) | 4 (2.1) | 1 (1.7) | 3 (2.8) | 0 (0) | 0.68 |
*p-values demonstrate comparison between UC and CD.
UC, ulcerative colitis; CD, Crohn’s disease; IBDU, Inflammatory Bowel Disease unclassified.